Terms: = Prostate cancer AND ENO2, HEL-S-279, NSE AND Treatment
60 results:
1. Brain metastasis in a patient with BRCA2-mutated treatment-related neuroendocrine prostate carcinoma and long-term response to radiotherapy and Olaparib: A case report and literature review.
Uehara R; Obinata D; Hashimoto S; Nakahara K; Uchida H; Yoshizawa T; Mochida J; Yamaguchi K; Sakaguchi M; Ozawa Y; Mori F; Miura K; Ishige T; Masuda S; Nakayama T; Takahashi S
Medicine (Baltimore); 2024 Mar; 103(9):e37371. PubMed ID: 38428891
[TBL] [Abstract] [Full Text] [Related]
2. Recent Progress in Biosensors for Detection of Tumor Biomarkers.
Li M; Jiang F; Xue L; Peng C; Shi Z; Zhang Z; Li J; Pan Y; Wang X; Feng C; Qiao D; Chen Z; Luo Q; Chen X
Molecules; 2022 Oct; 27(21):. PubMed ID: 36364157
[TBL] [Abstract] [Full Text] [Related]
3. Dynamic plasticity of prostate cancer intermediate cells during androgen receptor-targeted therapy.
Sandhu HS; Portman KL; Zhou X; Zhao J; Rialdi A; Sfakianos JP; Guccione E; Kyprianou N; Zhang B; Mulholland DJ
Cell Rep; 2022 Jul; 40(4):111123. PubMed ID: 35905714
[TBL] [Abstract] [Full Text] [Related]
4. Establishment and characterization of a novel treatment-related neuroendocrine prostate cancer cell line KUCaP13.
Okasho K; Mizuno K; Fukui T; Lin YY; Kamiyama Y; Sunada T; Li X; Kimura H; Sumiyoshi T; Goto T; Kobayashi T; Lin D; Wang Y; Collins CC; Inoue T; Ogawa O; Akamatsu S
Cancer Sci; 2021 Jul; 112(7):2781-2791. PubMed ID: 33960594
[TBL] [Abstract] [Full Text] [Related]
5. Efficacy of radical prostatectomy on prostate cancer patients and analysis of risk factors for biochemical recurrence after radical prostatectomy.
Yang X; Shi Y; Lin Y; Tian Y
J BUON; 2020; 25(6):2623-2628. PubMed ID: 33455105
[TBL] [Abstract] [Full Text] [Related]
6. Dermatomyositis associated with prostate adenocarcinoma with neuroendocrine differentiation.
Minagawa H; Kawai T; Matsumoto A; Makino K; Sato Y; Nagasaka K; Tokura M; Tanaka N; Ito E; Yamada Y; Nakamura M; Yamada D; Suzuki M; Murata T; Kume H
BMC Urol; 2021 Jan; 21(1):8. PubMed ID: 33413292
[TBL] [Abstract] [Full Text] [Related]
7. Evaluation of Blood-based Biomarkers for Prediction of Response in Carboplatin-treated Metastatic Castration-resistant prostate cancer Patients.
Moritz J; Bauernhofer T; Mannweiler S; Langsenlehner T; Pummer K; Dandachi N; Pichler M
In Vivo; 2020; 34(6):3631-3638. PubMed ID: 33144478
[TBL] [Abstract] [Full Text] [Related]
8. Molecular analysis of circulating tumor cells of metastatic castration-resistant prostate cancer Patients receiving
Kessel K; Seifert R; Weckesser M; Roll W; Humberg V; Schlack K; Bögemann M; Bernemann C; Rahbar K
Theranostics; 2020; 10(17):7645-7655. PubMed ID: 32685010
[No Abstract] [Full Text] [Related]
9. Androgen Deprivation Induces Reprogramming of prostate cancer Cells to Stem-Like Cells.
Sánchez BG; Bort A; Vara-Ciruelos D; Díaz-Laviada I
Cells; 2020 Jun; 9(6):. PubMed ID: 32531951
[TBL] [Abstract] [Full Text] [Related]
10. Comprehensive analysis of serum chromogranin A and neuron-specific enolase levels in localized and castration-resistant prostate cancer.
Szarvas T; Csizmarik A; Fazekas T; Hüttl A; Nyirády P; Hadaschik B; Grünwald V; Püllen L; Jurányi Z; Kocsis Z; Shariat SF; Sevcenco S; Maj-Hes A; Kramer G
BJU Int; 2021 Jan; 127(1):44-55. PubMed ID: 32314509
[TBL] [Abstract] [Full Text] [Related]
11. hASH1 nuclear localization persists in neuroendocrine transdifferentiated prostate cancer cells, even upon reintroduction of androgen.
Fraser JA; Sutton JE; Tazayoni S; Bruce I; Poole AV
Sci Rep; 2019 Dec; 9(1):19076. PubMed ID: 31836808
[TBL] [Abstract] [Full Text] [Related]
12. An Experimental Platform for Characterizing cancer Biomarkers with Capabilities in Noninvasive and Continuous Screening.
Honikel MM; La Belle JT
Crit Rev Biomed Eng; 2019; 47(3):217-234. PubMed ID: 31679257
[TBL] [Abstract] [Full Text] [Related]
13. Serum Neuroendocrine Markers Predict Therapy Outcome of Patients with Metastatic Castration-Resistant prostate cancer: A Meta-Analysis.
Liu Y; Zhao S; Wang J; Zhu Z; Luo L; Li E; Tang F; Zhao Z
Urol Int; 2019; 102(4):373-384. PubMed ID: 30517936
[TBL] [Abstract] [Full Text] [Related]
14. Asynchronous tumour quadruplicity: rectosigmoid adenocarcinoma, renal cell carcinoma, prostate adenocarcinoma and neuroendocrine small-cell lung cancer - a case report.
Adwan R; Prošvic P; Prošvicová J; Tomšová M
Rozhl Chir; 2018; 97(9):427-431. PubMed ID: 30470124
[TBL] [Abstract] [Full Text] [Related]
15. Cell-Free DNA and Neuromediators in Detecting Aggressive Variant prostate cancer.
von Hardenberg J; Worst TS; Westhoff N; Erben P; Fuxius S; Müller M; Bolenz C; Weiss C; Heinrich E
Oncol Res Treat; 2018; 41(10):627-633. PubMed ID: 30286478
[TBL] [Abstract] [Full Text] [Related]
16. Reduction of two histone marks, H3k9me3 and H3k27me3 by epidrug induces neuroendocrine differentiation in prostate cancer.
Lee E; Wang J; Jung Y; Cackowski FC; Taichman RS
J Cell Biochem; 2018 Apr; 119(4):3697-3705. PubMed ID: 29236331
[TBL] [Abstract] [Full Text] [Related]
17. Blocking the Feedback Loop between Neuroendocrine Differentiation and Macrophages Improves the Therapeutic Effects of Enzalutamide (MDV3100) on prostate cancer.
Wang C; Peng G; Huang H; Liu F; Kong DP; Dong KQ; Dai LH; Zhou Z; Wang KJ; Yang J; Cheng YQ; Gao X; Qu M; Wang HR; Zhu F; Tian QQ; Liu D; Cao L; Cui XG; Xu CL; Xu DF; Sun YH
Clin Cancer Res; 2018 Feb; 24(3):708-723. PubMed ID: 29191973
[No Abstract] [Full Text] [Related]
18. The role of serum neuron-specific enolase in patients with prostate cancer: a systematic review of the recent literature.
Muoio B; Pascale M; Roggero E
Int J Biol Markers; 2018 Jan; 33(1):10-21. PubMed ID: 28885659
[TBL] [Abstract] [Full Text] [Related]
19. Prospective Evaluation of Neuromediator Dynamics in Castration-Resistant prostate cancer Patients During Docetaxel.
VON Hardenberg J; Schwartz M; Werner T; Fuxius S; Müller M; Frangenheim T; Bolenz C; Weiss C; Heinrich E
Anticancer Res; 2017 Sep; 37(9):5117-5124. PubMed ID: 28870943
[TBL] [Abstract] [Full Text] [Related]
20. Influence of abiraterone acetate on neuroendocrine differentiation in chemotherapy-naive metastatic castration-resistant prostate cancer.
Dong B; Fan L; Wang Y; Chi C; Ma X; Wang R; Cai W; Shao X; Pan J; Zhu Y; Shangguan X; Xin Z; Hu J; Xie S; Kang X; Zhou L; Xue W
Prostate; 2017 May; 77(13):1373-1380. PubMed ID: 28804908
[TBL] [Abstract] [Full Text] [Related]
[Next]
